Resveratrol for patients with chronic obstructive pulmonary disease: Hype or hope?

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 21, Issue 2, 2018, Pages 138-144

  Beijers, Rosanne J H C G ^a   Gosker, Harry R ^a   Schols, Annemie M W J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

cardiovascular risk; chronic obstructive pulmonary disease; lung pathology; muscle mitochondrial function; resveratrol

Indexed keywords

RESVERATROL; ANTIOXIDANT;

AEROBIC METABOLISM; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BREATHING MUSCLE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; DRUG EFFECT; DRUG MECHANISM; HEART PROTECTION; HUMAN; LUNG INJURY; META ANALYSIS (TOPIC); MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MUSCLE MASS; MUSCLE METABOLISM; NONHUMAN; OXIDATIVE STRESS; REVIEW; SKELETAL MUSCLE; CARDIOVASCULAR SYSTEM; INFLAMMATION; LUNG; METABOLISM;

ANTIOXIDANTS; CARDIOVASCULAR SYSTEM; HUMANS; INFLAMMATION; LUNG; MITOCHONDRIA; MUSCLE, SKELETAL; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESVERATROL;

EID: 85042407993     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000444     Document Type: Review

References (70)

1. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. Gold executive summary. Am J Respir Crit Care Med 2017; 195:557-582.
2. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016; 138:16-27.
3. KirkhamPA, Barnes PJ. Oxidative stress inCOPD. Chest2013;144:266-273.
4. Patel AR, Hurst JR. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med 2011; 5:647-662.
5. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187:728-735.
6. Maltais F, Decramer M, Casaburi R, et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014; 189:e15-e62.
7. Gosker HR, Zeegers MP, Wouters EF, Schols AM. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax 2007; 62:944-949.
8. Natanek SA, Gosker HR, Slot IG, et al. Pathways associated with reduced quadriceps oxidative fibres and endurance in COPD. Eur Respir J 2013; 41:1275-1283.
9. Remels AH, Schrauwen P, Broekhuizen R, et al. Peroxisome proliferatoractivated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J 2007; 30:245-252.
10. van den Borst B, Slot IG, Hellwig VA, et al. Loss of quadriceps muscle oxidative phenotype and decreased endurance in patients with mild-to-moderate COPD. J Appl Physiol 2013; 114:1319-1328.
11. Gifford JR, Trinity JD, Layec G, et al. Quadriceps exercise intolerance in patients with chronic obstructive pulmonary disease: the potential role of altered skeletal muscle mitochondrial respiration. J Appl Physiol 2015; 119:882-888.
12. Puente-Maestu L, Tejedor A, Lazaro A, et al. Site of mitochondrial reactive oxygen species production in skeletal muscle of chronic obstructive pulmonary disease and its relationship with exercise oxidative stress. Am J Respir Cell Mol Biol 2012; 47:358-362.
13. Gea J, Pascual S, Casadevall C, et al. Muscle dysfunction in chronic obstructive pulmonary disease: Update on causes and biological findings. J Thorac Dis 2015; 7:E418-E438.
14. Siemann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Enol Viticult 1992; 43:49-52.
15. de Ligt M, Timmers S, Schrauwen P. Resveratrol and obesity: can resveratrol relieve metabolic disturbances? Biochim Biophys Acta 2015; 1852: 1137-1144.
16. Schrauwen P, Timmers S. Can resveratrol help to maintain metabolic health? Proc Nutr Soc 2014; 73:271-277.
17. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5:493-506.
18. Bitterman JL, Chung JH. Metabolic effects of resveratrol: addressing the controversies. Cell Mol Life Sci 2015; 72:1473-1488.
19. Timmers S, Hesselink MK, Schrauwen P. Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? Ann N Y Acad Sci 2013; 1290:83-89.
20. Cardozo LF, Pedruzzi LM, Stenvinkel P, et al. Nutritional strategies to modulate inflammation and oxidative stress pathways via activation of the master antioxidant switch nrf2. Biochimie 2013; 95:1525-1533.
21. Hwang JW, Yao H, Caito S, et al. Redox regulation of SIRT1 in inflammation and cellular senescence. Free Radic Biol Med 2013; 61:95-110.
22. Svajger U, Jeras M. Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases. Int Rev Immunol 2012; 31:202-222.
23. Yue L, Yao H. Mitochondrial dysfunction in inflammatory responses and cellular senescence: Pathogenesis and pharmacological targets for chronic lung diseases. Br J Pharmacol 2016; 173:2305-2318.
24. Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med 2014; 35:71-86.
25. KneppersAEM, Langen RCJ, Gosker HR, et al. Increasedmyogenic and protein turnover signaling in skeletal muscle of chronic obstructive pulmonary disease patients with sarcopenia. J Am Med Dir Assoc 2017; 18:637. e1-637. e11.
26. Kawai Y, Garduno L, Theodore M, et al. Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates its transcriptional activity and nucleocytoplasmic localization. J Biol Chem 2011; 286:7629-7640.
27. Cho S, Namkoong K, Shin M, et al. Cardiovascular protective effects and clinical applications of resveratrol. J Med Food 2017; 20:323-334.
28. Birrell MA, McCluskie K, Wong S, et al. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an Nf-kappaB-independent mechanism. FASEB J 2005; 19:840-841.
29. Culpitt SV, Rogers DF, Fenwick PS, et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 2003; 58:942-946.
30. Knobloch J, Sibbing B, Jungck D, et al. Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2010; 335:788-798.
31. Knobloch J, Wahl C, Feldmann M, et al. Resveratrol attenuates the release of inflammatory cytokines from human bronchial smooth muscle cells exposed to lipoteichoic acid in chronic obstructive pulmonary disease. Basic Clin Pharmacol Toxicol 2014; 114:202-209.
32. Liu H, Ren J, Chen H, et al. Resveratrol protects against cigarette smokeinduced oxidative damage and pulmonary inflammation. J Biochem Mol Toxicol 2014; 28:465-471.
33. Chen J, Yang X, Zhang W, et al. Therapeutic effects of resveratrol in a mouse model of LPS and cigarette smoke-induced COPD. Inflammation 2016; 39:1949-1959.
34. Hwang JW, Chung S, Sundar IK, et al. Cigarette smoke-induced autophagy is regulated by SIRT1-PARP-1-dependent mechanism: implication in pathogenesis of COPD. Arch Biochem Biophys 2010; 500:203-209.
35. Shi J, Yin N, Xuan LL, et al. Vam3, a derivative of resveratrol, attenuates cigarette smoke-induced autophagy. Acta Pharmacol Sin 2012; 33:888-896.
36. Hoffmann RF, Zarrintan S, Brandenburg SM, et al. Prolonged cigarette smoke exposure alters mitochondrial structure and function in airway epithelial cells. Respir Res 2013; 14:97.
37. Kode A, Rajendrasozhan S, Caito S, et al. Resveratrol induces glutathione synthesis by activation of nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2008; 294:L478-488.
38. Li S, Zhao G, Chen L, et al. Resveratrol protects mice from paraquat-induced lung injury: the important role of sirt1 and nrf2 antioxidant pathways. Mol Med Rep 2016; 13:1833-1838.
39. Navarro S, Reddy R, Lee J, et al. Inhaled resveratrol treatments slow ageingrelated degenerative changes in mouse lung. Thorax 2017; 72:451-459.
40. Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004; 1:264-268.
41. Saag KG, Furst DE. Major side effects of systemic glucocorticoids. Waltham, MA: UpToDate Inc; 2017; Available from: https://www. uptodate. com/contents/ major-side-effects-of-systemic-glucocorticoids. [Accessed: 28 June 2017]
42. Knobloch J, Hag H, Jungck D, et al. Resveratrol impairs the release of steroidresistant cytokines from bacterial endotoxin-exposed alveolar macrophages in chronic obstructive pulmonary disease. Basic Clin Pharmacol Toxicol 2011; 109:138-143.
43. Trotta V, Lee WH, Loo CY, et al. In vitro biological activity of resveratrol using a novel inhalable resveratrol spray-dried formulation. Int J Pharm 2015; 491:190-197.
44. Trotta V, Lee WH, Loo CY, et al. Co-spray dried resveratrol and budesonide inhalation formulation for reducing inflammation and oxidative stress in rat alveolar macrophages. Eur J Pharm Sci 2016; 86:20-28.
45. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14:612-622.
46. Goh KP, Lee HY, Lau DP, et al. Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle sirt1 expression and energy expenditure. Int J Sport Nutr Exerc Metab 2014; 24:2-13.
47. Poulsen MM, Vestergaard PF, Clasen BF, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebocontrolled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013; 62:1186-1195.
48. Yoshino J, Conte C, Fontana L, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 2012; 16:658-664.
49. Most J, Timmers S, Warnke I, et al. Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial. Am J Clin Nutr 2016; 104:215-227.
50. Timmers S, de Ligt M, Phielix E, et al. Resveratrol as add-on therapy in subjects with well controlled type 2 diabetes: a randomized controlled trial. Diabetes Care 2016; 39:2211-2217.
51. Pollack RM, Barzilai N, Anghel V, et al. Resveratrol improves vascular function and mitochondrial number but not glucose metabolism in older adults. J Gerontol A Biol Sci Med Sci 2017; 72:1703-1709.
52. Hyatt JP, Nguyen L, Hall AE, et al. Muscle-specific myosin heavy chain shifts in response to a long-term high fat/high sugar diet and resveratrol treatment in nonhuman primates. Front Physiol 2016; 7:77.
53. Qi Y, Shang JY, Ma LJ, et al. Inhibition of AMPK expression in skeletal muscle by systemic inflammation in COPD rats. Respir Res 2014; 15:156.
54. Alamdari N, Aversa Z, Castillero E, et al. Resveratrol prevents dexamethasoneinduced expression of the muscle atrophy-related ubiquitin ligases atrogin-1 and murf1 in cultured myotubes through a SIRT1-dependent mechanism. Biochem Biophys Res Commun 2012; 417:528-533.
55. Liu J, Peng Y, Wang X, et al. Mitochondrial dysfunction launches dexamethasone-induced skeletal muscle atrophy via AMPK/FOXO3 signaling. Mol Pharm 2016; 13:73-84.
56. Wang DT, Yin Y, Yang YJ, et al. Resveratrol prevents TNF-alpha-induced muscle atrophy via regulation of Akt/mTOR/FoxO1 signaling in c2c12 myotubes. Int Immunopharmacol 2014; 19:206-213.
57. Sadeghi A, Seyyed Ebrahimi SS, Golestani A, Meshkani R. Resveratrol ameliorates palmitate-induced inflammation in skeletal muscle cells by attenuating oxidative stress and JNK/NF-kB pathway in a SIRT1-independent mechanism. J Cell Biochem 2017; 118:2654-2663.
58. Remels AH, Gosker HR, Langen RC, Schols AM. The mechanisms of cachexia underlying muscle dysfunction in COPD. J Appl Physiol 2013; 114:1253-1262.
59. Kjaer TN, Ornstrup MJ, Poulsen MM, et al. No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. J Clin Endocrinol Metab 2017; 102:1642-1651.
60. Bonnefont-Rousselot D. Resveratrol and cardiovascular diseases. Nutrients 2016; 8:250.
61. Zordoky BN, Robertson IM, Dyck JR. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta 2015; 1852:1155-1177.
62. Huang H, Chen G, Liao D, et al. The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials. Obes Rev 2016; 17:1329-1340.
63. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci 2011; 1215:9-15.
64. Beijers R, van de Bool C, van den Borst B, et al. Normal weight but low muscle mass and abdominally obese: implications for the cardiometabolic risk profile in chronic obstructive pulmonary disease. J Am Med Dir Assoc 2017; 18:533-538.
65. Cebron Lipovec N, Schols AM, van den Borst B, et al. Sarcopenia in advanced COPD affects cardiometabolic risk reduction by short-term high-intensity pulmonary rehabilitation. J Am Med Dir Assoc 2016; 17:814-820.
66. Liu XJ, Bao HR, Zeng XL, Wei JM. Effects of resveratrol and genistein on nuclear factor kappaB, tumor necrosis factor alpha and matrix metalloproteinase9 in patients with chronic obstructive pulmonary disease. Mol Med Rep 2016; 13:4266-4272.
67. Remels AH, Gosker HR, Langen RC, et al. Classical Nf-kappaB activation impairs skeletal muscle oxidative phenotype by reducing IKK-alpha expression. Biochim Biophys Acta 2014; 1842:175-185.
68. Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177:861-870.
69. Passey SL, Hansen MJ, Bozinovski S, et al. Emerging therapies for the treatment of skeletal muscle wasting in chronic obstructive pulmonary disease. Pharmacol Ther 2016; 166:56-70.
70. Ceelen JJ, Langen RC, Schols AM. Systemic inflammation in chronic obstructive pulmonary disease and lung cancer: Common driver of pulmonary cachexia? Curr Opin Support Palliat Care 2014; 8:339-345.